Fixed Triple Therapy in Chronic Obstructive Pulmonary Disease and Survival. Living Better, Longer, or Both?

Jørgen Vestbo^{1

2}

Affiliations

¹ Division of Infection, Immunity, and Respiratory MedicineThe University of ManchesterManchester, United Kingdomand.
² North West Lung CentreManchester University NHS Foundation TrustManchester, United Kingdom.

Editorial

Jørgen Vestbo. Am J Respir Crit Care Med. 2020.

. 2020 Jun 15;201(12):1463-1464.

doi: 10.1164/rccm.202003-0622ED.

Jørgen Vestbo^{1

2}

¹ Division of Infection, Immunity, and Respiratory MedicineThe University of ManchesterManchester, United Kingdomand.
² North West Lung CentreManchester University NHS Foundation TrustManchester, United Kingdom.

No abstract available

Comment on

Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol in Patients with Chronic Obstructive Pulmonary Disease.
Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, Kilbride S, Lange P, Lomas DA, Lettis S, Manchester P, Martin N, Midwinter D, Morris A, Pascoe SJ, Singh D, Wise RA, Martinez FJ. Lipson DA, et al. Am J Respir Crit Care Med. 2020 Jun 15;201(12):1508-1516. doi: 10.1164/rccm.201911-2207OC. Am J Respir Crit Care Med. 2020. PMID: 32162970 Free PMC article. Clinical Trial.

1. Lipson DA, Crim C, Criner GJ, Day NC, Dransfield MT, Halpin DMG, et al. IMPACT Investigators. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201:1508–1516. - PMC - PubMed
1. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680. - PubMed
1. Pascoe SJ, Lipson DA, Locantore N, Barnacle H, Brealey N, Mohindra R, et al. A phase III randomised controlled trial of single-dose triple therapy in COPD: the IMPACT protocol. Eur Respir J. 2016;48:320–330. - PubMed
1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, et al. TORCH investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789. - PubMed
1. Vestbo J, Anderson JA, Brook RD, Calverley PM, Celli BR, Crim C, et al. SUMMIT Investigators. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet. 2016;387:1817–1826. - PubMed